NCT03330353View on ClinicalTrials.gov

Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy

UnknownOBSERVATIONAL
Enrollment

56

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

October 1, 2019

Study Completion Date

October 1, 2019

Conditions
PSP - Progressive Supranuclear PalsyPD - Parkinson's DiseaseAD - Alzheimer's DiseaseALS (Amyotrophic Lateral Sclerosis)
Interventions
DIAGNOSTIC_TEST

Pupillometry

Use of pupillometry to assess melanopsin-light pathway in patients with neurodegenerative diseases

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

NeurOptics Inc.
All Listed Sponsors
collaborator

NeurOptics Inc.

INDUSTRY

collaborator

University of Toronto

OTHER

lead

Massachusetts General Hospital

OTHER